PGEN (Precigen) GF Value : $0.23 (As of Dec. 15, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Precigen GF Value?

As of today (2024-12-15), Precigen's share price is $0.6753. Precigen's GF Value is $0.23. Therefore, Precigen's Price-to-GF-Value for today is 2.94. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Precigen is Significantly Overvalued.

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

Precigen (NAS:PGEN) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Precigen's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.6753	/	0.23
	=	2.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Precigen GF Value Related Terms

Thank you for viewing the detailed overview of Precigen's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Precigen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precigen Inc (NAS:PGEN) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

I5X:Germany

Address

20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876

Website

http://www.precigen.com

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Executives

Randal J Kirk	director, 10 percent owner, officer: Chief Executive Officer	1881 GROVE AVENUE, RADFORD VA 24141
Jeffrey Thomas Perez	officer: SVP, IP Affairs	20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Jeffrey B Kindler	director	35 E. 62ND ST, NEW YORK NY 10065
Dean J Mitchell	director	C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Helen Sabzevari	director, officer: President and CEO	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Rutul R Shah	officer: Chief Operating Officer	C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Harry Jr. Thomasian	officer: Chief Financial Officer	C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD 20876
Donald P. Lehr	officer: Chief Legal Officer	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Fred Hassan	director	C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Steven Frank	director	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Vinita D Gupta	director	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Robert B Shapiro	director	155 WEST BURTON PLACE, #2, CHICAGO IL 60610
Cesar L Alvarez	director	C/O PEDIATRIX MEDICAL GROUP, LEGAL DEPT 1301- CONCORD TERRACE, SUNRISE FL 33323
James S Turley	director	9 MUIRFIELD LANE, SAINT LOUIS MO 63141
Ares Trading S.a.	10 percent owner	ZONE INDUSTRIELLE DE L'OURIETTAZ, AUBONNE V8 1170